By Connor Hart
Insulet named Ashley McEvoy as its chief executive, taking the reins from Jim Hollingshead.
McEvoy has nearly three decades of experience, the medical-devices company said Monday. She most recently served as executive vice president of Johnson & Johnson's MedTech business, and previously held various roles of increasing responsibility at the healthcare conglomerate.
She has served as a member of Procter & Gamble's board since 2023.
McEvoy, who will additionally serve as president and has joined Insulet's board, said the Action, Mass., company has untapped growth potential, adding that she hopes to enhance innovation and drive global expansion during her tenure.
She succeeds Hollingshead, who mutually agreed with the Insulet's board that it was the right time to transition leadership, the company said. He has entered a consulting arrangement with the company to facilitate a smooth transition.
With the disclosure of its new top officer, Insulet said it will reschedule its investor day conference, initially planned for June 5, to a later day.
It also expects to exceed its previously provided first-quarter revenue outlook and raise its full-year guidance. The company is scheduled to release its first-quarter earnings on May 8.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 28, 2025 06:26 ET (10:26 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.